Amicogen KRX:092040KOSDAQ
아미코젠 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days3
DART filings, 7 days0
Articles tracked15since Sep 11
In Q2 2026, Amicogen reported revenue of ₩13.4bn, up 32.0% year on year, and an operating loss of ₩1.3bn. Amicogen (아미코젠) appeared in 3 Korean news articles and 0 DART filings over the past seven days. Coverage peaked on Oct 19 with 5 articles. The most common catalyst was tech & capacity (6). It was most often mentioned alongside 글로벌테크놀로지.
Filing signals Revenue +30% 4 quarters of losses Screener
Amicogen quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩13.4bn | +32.0% | −₩1.3bn margin −9.7% | −₩20.8bn |
| Q1 2026 | ₩12.3bn | +13.5% | −₩3.2bn margin −25.8% | ₩19.4bn |
| Q4 2025 derived | ₩10.9bn | -80.9% | −₩3.9bn margin −35.8% | −₩5.5bn |
| Q3 2025 | ₩10.1bn | -74.6% | −₩4.7bn margin −46.1% | −₩13.0bn |
| Q2 2025 | ₩10.1bn | -76.2% | −₩4.2bn margin −41.8% | −₩6.0bn |
| Q1 2025 | ₩10.8bn | -68.3% | −₩4.3bn margin −40.0% | −₩5.8bn |
| Q4 2024 derived | ₩56.9bn | +45.8% | −₩802m margin −1.4% | −₩38.7bn |
| Q3 2024 | ₩39.9bn | -7.5% | −₩1.4bn margin −3.4% | ₩2.0bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Amicogen top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest Amicogen news Korean headlines
-
아미코젠, 차세대 7-ACA 합성 효소 유럽 특허 등록 결정…"글로벌 공략 가속화"
2 more on this story · 2 outlets
- 아미코젠, 7-ACA 합성 효소 유럽 특허 등록뉴스핌 · Oct 19 09:03
- 아미코젠, 차세대 7-ACA 합성 효소 유럽 특허 등록머니투데이 · Oct 19 09:06
-
아미코젠 자체 배지 'UltiMax G2', 비교평가서 항체 생산량 1위
1 more on this story · 1 outlets
- 아미코젠 자체 배지, 항체 생산량 비교평가서 글로벌 제품 앞서메디컬투데이 · Oct 8 10:41